drugset / Trial / NCT01310478
Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To investigate safety and tolerance of dose-escalation of infusional recombinant human endostatin in combination with mFOLFOX6 as initial therapy for patients with metastatic colorectal cancer.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |
| Subject | Endostar | Protein / enzyme biologic | 45 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2.4 unknown | — |
| Background | fluorouracil | Small molecule | 400 mg/m2 | — |